SPRY
ARS Pharmaceuticals, Inc
NASDAQ: SPRY · HEALTHCARE · BIOTECHNOLOGY
$8.26
+5.36% today
Updated 2026-04-30
Market cap
$788.42M
P/E ratio
—
P/S ratio
9.36x
EPS (TTM)
$-1.74
Dividend yield
—
52W range
$7 – $19
Volume
1.5M
ARS Pharmaceuticals, Inc (SPRY) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-203.30%
Operating margin
-147.60%
ROE
-92.30%
ROA
-33.00%
Debt/equity
0.01x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2018 | — | $-17.58M | — | — | — |
| 2019 | — | $-23.97M | — | — | — |
| 2020 | $17.84M | $-1.06M | 21.11% | -2.63% | -5.97% |
| 2021 | $5.51M | $-20.24M | 96.13% | -353.32% | -367.65% |
| 2022 | $1.32M | $-34.68M | -1,200.91% | -2,698.78% | -2,635.41% |
| 2023 | $30000.00 | $-54.37M | 100.00% | -225,066.67% | -181,216.67% |
| 2024 | $89.15M | $8.00M | 76.94% | -3.46% | 8.97% |
| 2025 | $84.28M | $-171.30M | 75.77% | -212.92% | -203.25% |